Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + tepotinib in platinum-resistant head and neck squamous cell carcinoma after immunotherapy
2024-518892-72-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and tepotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Objective response rate (ORR). Planned start Jan 2025; status: authorised.
02
Drugs
cetuximabtepotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-518892-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518892-72-00.